Participation at BIO International Convention 2026
Genflow Biosciences Plc announced that its Independent Non-Executive Chairman will attend the BIO International Convention from June 22-25 in San Diego, California, to participate in a panel discussion on RNA therapeutics. This participation at a major biotechnology industry event aims to discuss scientific innovation and emerging technologies relevant to the company's longevity research, including its lead compound GF-1002, a centenarian variant of the SIRT6 gene, which has shown promising preclinical results and is being evaluated in aged dogs and for MASH treatment.
Select text to share a quote on X · sign in to keep highlights & notes in your GENF notes
Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad Berdugo, Independent Non-Executive Chairman will attend the BIO International Convention June 22-25 in San Diego, California.
- Berdugo will participate in the panel discussion titled: "RNA Therapeutics: Where Will We See the Greatest Technical Advances and Continued Clinical Validation in the Next 3-5 Years?"
The BIO International Convention is one of the world's largest biotechnology industry events, bringing together biotechnology companies, academic and research institutions, investors, policymakers and industry leaders from across the globe to discuss scientific innovation, emerging technologies and the future of healthcare.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.